PerkinElmer, Inc.
About PerkinElmer, Inc.
712 articles with PerkinElmer, Inc.
-
PerkinElmer Supports JUMP-CP Consortium Creating World’s Largest, Public Cell Painting Dataset
6/7/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is providing its PhenoVue™ Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium
-
Welsh Lighthouse Laboratory Extends Contract with PerkinElmer for its COVID-19 Solutions
5/27/2021
Company’s RT-PCR kits and workflow solutions will continue to safeguard capacity for NHS Test and Trace laboratory
-
PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
5/17/2021
PerkinElmer, Inc. and Immunodiagnostic Systems Holdings PLC are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million.
-
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
-
PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience
5/12/2021
PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash.
-
PerkinElmer Announces Financial Results for the First Quarter of 2021
5/4/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 4, 2021.
-
PerkinElmer to Host Virtual Investor and Analyst Day
5/4/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the Company will host a virtual Investor and Analyst Day on Thursday, June 24, 2021 from 8:30 a.m. to 12:00 p.m. ET.
-
PerkinElmer Board Declares Quarterly Dividend - Apr 29, 2021
4/29/2021
The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock April 29, 2021.
-
PerkinElmer to Present at BofA Securities 2021 Virtual Health Care Conference
4/21/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12, 2021 at 9:30 a.m. ET.
-
PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021
4/13/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021.
-
PerkinElmer Launches Industry-First CRM Reagent and Consumable Kit to Streamline Cannabis Pesticide Testing Workflows
3/18/2021
PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today launched its ONE Pesticide 420 ™ CRM Reagent and Consumable Kit for cannabis & hemp testing. Initially the kits will support pesticide and mycotoxin testing
-
PerkinElmer Further Expands Industry-Leading Signals™ Informatics Capabilities in Biologics Drug Discovery
3/17/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space.
-
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
3/9/2021
PerkinElmer, Inc. , (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product,
-
PerkinElmer Adds HPLC Columns to Consumables Portfolio
3/8/2021
PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries , based in West Berlin, New Jersey in the U.S.
-
PerkinElmer Prices Offering of Senior Notes - Mar 05, 2021
3/5/2021
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that it has priced an offering of $400.0 million aggregate principal amount of 2.550% Senior Notes due 2031 at an issue price of 99.965% of the principal amount and $400.0 million aggregate principal amount of 3.625% Senior Notes due 2051 at an issue price of 99.999% of the principal amount.
-
PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening
2/23/2021
Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR
-
PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process
2/22/2021
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process.
-
PerkinElmer Launches First Cell Painting Kit
2/16/2021
New PhenoVue™ cell painting reagent kit makes the process of “painting” cells easier for research scientists by providing carefully selected and pre-optimized reagents
-
PerkinElmer to Present at Cowen Health Care Conference
2/16/2021
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41 st Annual Cowen Health Care Conference on Monday, March 1, 2021 from 12:20 p.m. to 12:50 p.m. ET.
-
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2020
2/2/2021
4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance